Merck's Januvia meets in CV outcomes trial

Merck & Co. Inc. (NYSE:MRK) said the TECOS cardiovascular outcomes trial (CVOT) of Januvia sitagliptin met the primary endpoint of non-inferiority vs. placebo in time to first CV

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE